Discover
SPRY
ARS Pharmaceuticals, Inc.
4.23
2 x 3.89
2 x 6.72
bid
ask
-
0.33
7.24%
2 @ 05:50 PM
4.33 +0.10 (2.36%)
| Ytd | -63.69% | |
| 1y | -63.47% |
4.20
day range
4.55
4.07
52 week range
13.06
| Open | 4.55 | Prev Close | 4.56 | Low | 4.20 | High | 4.55 | Mkt Cap | 420.66M |
| Vol | 1.26M | Avg Vol | 1.86M | EPS | -2.18 | P/E | N/A | Forward P/E | -11.01 |
| Beta | 0.83 | Short Ratio | 13.70 | Inst. Own | 95.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-10 | 50-d Avg | 5.15 | 200-d Avg | 7.99 | 1yr Est | 28.80 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-13 | 2026-06 | -0.48 | N/A | N/A | N/A |
| 2026-05-15 | 2026-03 | -0.53 | -0.61 | -0.08 | -15.09% |
| 2026-03-09 | 2025-12 | -0.42 | -0.42 | N/A | N/A |
| 2025-11-10 | 2025-09 | -0.45 | -0.52 | -0.07 | -15.56% |
| 2025-08-13 | 2025-06 | -0.41 | -0.46 | -0.05 | -12.20% |
| 2025-05-14 | 2025-03 | -0.35 | -0.35 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-05-28 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2025-09-04 | Roth Capital | Upgrade | Buy | |
| 2025-03-07 | Scotiabank | Upgrade | Sector Outperform | |
| 2025-01-14 | Raymond James | Upgrade | Strong Buy | Strong Buy |
| 2025-01-13 | Leerink Partners | Upgrade | Outperform | Outperform |
| 2024-10-08 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-11 | FITZPATRICK ALEXANDER A. | Officer | 90.91K | Sale |
| 2025-06-26 | FLYNN JAMES E | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-06-11 | KARAS ERIC | Officer | 12.18K | Sale |
| 2025-08-20 | LOWENTHAL RICHARD E | Chief Executive Officer | 0.00 | Sale |
| 2024-08-25 | ORBIMED ADVISORS, L.L.C. | Unknown | 0.00 | Sale |
| 2025-08-20 | SCOTT KATHLEEN D | Chief Financial Officer | 18.29K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, L.P. | 10.86M | 114.47M | 10.94% |
| 2026-03-30 | Orbimed Advisors LLC. | 8.29M | 87.36M | 8.35% |
| 2026-03-30 | Rubric Capital Management LP | 8.00M | 84.32M | 8.06% |
| 2026-03-30 | Deerfield Management Company, L.P | 7.50M | 79.09M | 7.56% |
| 2026-03-30 | Millennium Management Llc | 5.98M | 63.06M | 6.02% |
| 2026-03-30 | Blackrock Inc. | 5.01M | 52.83M | 5.05% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.42M | 25.49M | 2.44% |
| 2026-03-30 | abrdn Healthcare Opportunities Fund | 1.78M | 18.80M | 1.80% |
| 2026-03-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.75M | 18.44M | 1.76% |
| 2026-03-30 | abrdn Healthcare Investors | 1.55M | 16.32M | 1.56% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 1.39M | 14.68M | 1.40% |
| 2026-03-30 | BARON INVESTMENT Fd.S TRT -BARON DISCOVERY Fd. | 1.07M | 11.33M | 1.08% |